Aflac AFL Cancer — Weighted-average interest, original discount rate
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — weighted-average interest, original discount rate.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aflac's cancer — weighted-average interest, original discount rate?
- Aflac (AFL) reported cancer — weighted-average interest, original discount rate of 3.8% in Q1 2026.
- How has Aflac's cancer — weighted-average interest, original discount rate changed year-over-year?
- Aflac's cancer — weighted-average interest, original discount rate decreased by 2.6% year-over-year, from 3.9% to 3.8%.
- What is the long-term trend for Aflac's cancer — weighted-average interest, original discount rate?
- Over 2 years (2023 to 2025), Aflac's cancer — weighted-average interest, original discount rate has grown at a -1.0% compound annual growth rate (CAGR), from 15.6% to 15.3%.
- What does cancer — weighted-average interest, original discount rate mean?
- This represents the weighted average interest rate used to discount future policy benefit liabilities at the time of policy inception. It serves as a baseline for calculating the present value of long-term obligations based on the economic environment at the time the contract was issued. This rate is essential for understanding the historical cost of capital associated with the cancer insurance portfolio.